In autoimmune diseases, the challenge is that the immune system “attacks” its own tissues. The PolTREG approach focuses on using TREG cells – the natural “regulators” of immunity – to restore immune balance, rather than solely suppressing symptoms.
The company is developing therapies and clinical programs to treat or modify the course of type 1 diabetes (T1D), therapies for patients with multiple sclerosis (MS) and further autoimmune indications, among others, as part of a platform under development